[{"data":1,"prerenderedAt":152},["ShallowReactive",2],{"drug-umeclidinium":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":57,"warnings":67,"renal":75,"monitoring":76,"interactions":77,"review":78,"examples":81,"atc":87,"iran":89,"usApproval":96,"links":102,"populations":117},"umeclidinium",1,{"fa":7,"en":8},"یومکلیدینیوم","Umeclidinium","respiratory",{"fa":11,"en":12},"آنتی‌موسکارینی طولانی‌اثر (LAMA)","Long-acting muscarinic antagonist (LAMA)",[14],{"name":15,"market":16},"Incruse Ellipta","US",[18,19,7],"incruse","اینکروز",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"ellipta","inhaler","inhaled","62.5 mcg per actuation (Ellipta)",{"amount":27,"unit":28,"perUnit":29},62.5,"mcg","actuation",[16],[32],{"source":33,"section":34},"fda-incruse","3",[36],{"id":37,"disease":37,"label":38,"population":41,"type":45,"unit":28,"dose":46,"refs":47,"notes":50},"copd",{"fa":39,"en":40},"نگهدارنده COPD — یک استنشاق (۶۲٫۵ mcg) یک بار در روز","COPD maintenance — 1 inhalation (62.5 mcg) once daily",{"minAge":42},{"value":43,"unit":44},18,"year","fixed",{"perDose":27,"dosesPerDay":5},[48],{"source":33,"section":49},"2",[51],{"text":52,"refs":55},{"fa":53,"en":54},"هر روز یک ساعت ثابت؛ بیش از یک بار در ۲۴ ساعت نه. سالمند، نارسایی کلیه یا نارسایی متوسط کبد تنظیم ندارد.","Same time every day; not more than once every 24 h. No adjustment for elderly, renal impairment or moderate hepatic impairment.",[56],{"source":33,"section":49},[58],{"id":59,"severity":60,"text":61,"refs":64},"ci","block",{"fa":62,"en":63},"حساسیت شدید به پروتئین شیر؛ حساسیت به یومکلیدینیوم.","Severe hypersensitivity to milk proteins; hypersensitivity to umeclidinium.",[65],{"source":33,"section":66},"4",[68],{"text":69,"refs":72},{"fa":70,"en":71},"برای حمله حاد نیست؛ برونکواسپاسم متناقض؛ تشدید گلوکوم زاویه بسته و احتباس ادرار؛ حساسیت.","Not for acute episodes; paradoxical bronchospasm; worsening narrow-angle glaucoma and urinary retention; hypersensitivity.",[73],{"source":33,"section":74},"5",[],[],[],{"status":79,"reviewer":80,"date":80},"unverified",null,[82],{"regimen":37,"formulation":22,"input":83,"expect":86},{"ageYears":84,"weightKg":85},65,70,{"perDose":27,"tabletsPerDoseRounded":5},[88],"R03BB07",{"status":90,"refs":91},"not-found",[92],{"source":93,"section":94,"url":95},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Umeclidinium",{"kind":97,"refs":98,"id":101},"NDA",[99],{"source":33,"section":100},"SPL approval \u002F marketing category","NDA205382",[103,106,110,114],{"kind":104,"url":105,"label":101},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=205382",{"kind":107,"url":108,"label":109},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=dbb64747-1505-49d7-9a33-99dd402e96d3","FDA Incruse Ellipta",{"kind":111,"url":112,"label":113},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa614024.html","Umeclidinium Oral Inhalation",{"kind":115,"url":116,"label":88},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=R03BB07",{"pregnancy":118,"lactation":127,"pediatric":135,"geriatric":143},{"level":119,"text":120,"quote":123,"refs":124},"caution",{"fa":121,"en":122},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are insufficient data on the use of umeclidinium in pregnant women to inform a drug‑associated risk.",[125],{"source":33,"section":126},"8.1",{"level":119,"text":128,"quote":131,"refs":132},{"fa":129,"en":130},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information available on the presence of umeclidinium in human milk, the effects on the breastfed child, or the effects on milk production.",[133],{"source":33,"section":134},"8.2",{"level":119,"text":136,"quote":139,"refs":140},{"fa":137,"en":138},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of INCRUSE ELLIPTA have not been established in pediatric patients.",[141],{"source":33,"section":142},"8.4",{"level":144,"text":145,"quote":148,"refs":149},"ok",{"fa":146,"en":147},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger subjects.",[150],{"source":33,"section":151},"8.5",1792191571369]